Skip to content

Targeting JOSD2 degrades β-catenin to suppress colorectal cancer metastasis by disrupting RAS/ERK/β-catenin axis.

Jul 2026 · Acta Pharmacologica Sinica · 0 citations · 40 references
Medicine
View source